Revium Rx. (RVRC)
OTCMKTS · Delayed Price · Currency is USD
1.670
+0.170 (11.33%)
At close: Mar 30, 2026

Revium Rx. Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2009
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '09
-----0.66
Revenue Growth (YoY)
------77.96%
Cost of Revenue
-----0.55
Gross Profit
-----0.1
Selling, General & Admin
1.571.821.410.161.120.21
Research & Development
1.91.642.160.850.07-
Operating Expenses
3.473.463.5711.190.21
Operating Income
-3.47-3.46-3.57-1-1.19-0.1
Interest Expense
---0--0.02-
Interest & Investment Income
0.060.060.07---
Other Non Operating Income (Expenses)
-0.09--0.02--
EBT Excluding Unusual Items
-3.5-3.41-3.51-0.99-1.21-0.1
Impairment of Goodwill
-8.65-8.65----
Asset Writedown
-1.04-1.04----
Pretax Income
-13.18-13.09-3.51-0.99-1.21-0.1
Income Tax Expense
0.360.36----
Net Income
-13.54-13.45-3.51-0.99-1.21-0.1
Preferred Dividends & Other Adjustments
----0.99--
Net Income to Common
-13.54-13.45-3.51--1.21-0.1
Shares Outstanding (Basic)
61612629280
Shares Outstanding (Diluted)
61612629280
Shares Change (YoY)
48.92%136.92%-12.69%4.44%48170.60%-15.69%
EPS (Basic)
-0.22-0.22-0.14--0.04-1.78
EPS (Diluted)
-0.22-0.22-0.14--0.04-1.78
Free Cash Flow
-2.72-2.54-1.21-1.02-0.823.23
Free Cash Flow Per Share
-0.04-0.04-0.05-0.04-0.0355.51
Gross Margin
-----15.59%
Operating Margin
------15.79%
Profit Margin
------15.79%
Free Cash Flow Margin
-----491.85%
EBITDA
-3.46-3.46-3.56-1-1.19-
D&A For EBITDA
0.010.01000-
EBIT
-3.47-3.46-3.57-1-1.19-0.1
EBIT Margin
------15.79%